NCT04351295View on ClinicalTrials.gov

Efficacy of Faviprevir in COVID-19 Treatment

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

April 20, 2020

Primary Completion Date

September 28, 2020

Study Completion Date

September 28, 2020

Conditions
COVID
Interventions
DRUG

Favipiravir

Favipiravir

DRUG

Chloroquine

chloroquine oral tablets

Trial Locations (1)

35111

Tanta University, Ainshams University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT04351295 - Efficacy of Faviprevir in COVID-19 Treatment | Biotech Hunter | Biotech Hunter